HTML Microdata document

This HTML5 document contains 111 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n30	http://www.rxlist.com/cgi/generic3/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n13	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/chemspider/
n20	http://linked.opendata.cz/resource/AHFS/
n25	http://linked.opendata.cz/resource/mesh/concept/
foaf	http://xmlns.com/foaf/0.1/
n4	http://linked.opendata.cz/resource/drugbank/company/
n23	http://linked.opendata.cz/resource/drugbank/dosage/
n7	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/chebi/
n22	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/wikipedia/
n31	http://bio2rdf.org/drugbank:
n15	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/pharmgkb/
n12	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/kegg-compound/
adms	http://www.w3.org/ns/adms#
n16	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/pubchem-compound/
n5	http://linked.opendata.cz/resource/drugbank/patent/
n9	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n11	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/pubchem-substance/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n21	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n17	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/kegg-drug/
n24	http://linked.opendata.cz/ontology/mesh/
n3	http://linked.opendata.cz/ontology/drugbank/
n27	http://www.drugs.com/cdi/
n14	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/drugbank/
n10	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n18	http://linked.opendata.cz/resource/drugbank/drug/DB01200/identifier/national-drug-code-directory/
n29	http://linked.opendata.cz/resource/atc/
n19	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB01200
rdf:type: n3:Drug
n3:description: Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.
n3:dosage: n23:271B5465-363D-11E5-9242-09173F13E4C5 n23:271B5466-363D-11E5-9242-09173F13E4C5 n23:271B5467-363D-11E5-9242-09173F13E4C5 n23:271B5468-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # Banihashemi B, Albert PR: Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: distinct Galpha and Gbetagamma requirements. Mol Endocrinol. 2002 Oct;16(10):2393-404. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12351703 # Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18691132 # Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10641988 # Malgaroli A, Vallar L, Elahi FR, Pozzan T, Spada A, Meldolesi J: Dopamine inhibits cytosolic Ca2+ increases in rat lactotroph cells. Evidence of a dual mechanism of action. J Biol Chem. 1987 Oct 15;262(29):13920-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2443499 # Nishina Y, Takano K, Yasufuku-Takano J, Teramoto A, Fujita T: Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells. Endocr J. 2005 Dec;52(6):775-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16410672 # Vallar L, Meldolesi J: Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci. 1989 Feb;10(2):74-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2655242 # Vallar L, Vicentini LM, Meldolesi J: Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem. 1988 Jul 25;263(21):10127-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2839476
n3:group: approved investigational
n3:halfLife: 2-8 hours
n3:indication: For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
owl:sameAs: n9:DB01200 n31:DB01200
dcterms:title: Bromocriptine
adms:identifier: n7:3181 n11:46505504 n12:C06856 n13:28858 n14:DB01200 n15:PA448671 n16:31101 n17:D03165 n18:0078-0017-15 n22:Bromocriptine
n3:mechanismOfAction: The dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders.
n3:packager: n4:271B5450-363D-11E5-9242-09173F13E4C5 n4:271B5451-363D-11E5-9242-09173F13E4C5 n4:271B544E-363D-11E5-9242-09173F13E4C5 n4:271B544F-363D-11E5-9242-09173F13E4C5 n4:271B544C-363D-11E5-9242-09173F13E4C5 n4:271B544D-363D-11E5-9242-09173F13E4C5 n4:271B545A-363D-11E5-9242-09173F13E4C5 n4:271B5458-363D-11E5-9242-09173F13E4C5 n4:271B5459-363D-11E5-9242-09173F13E4C5 n4:271B5456-363D-11E5-9242-09173F13E4C5 n4:271B5457-363D-11E5-9242-09173F13E4C5 n4:271B5454-363D-11E5-9242-09173F13E4C5 n4:271B5455-363D-11E5-9242-09173F13E4C5 n4:271B544B-363D-11E5-9242-09173F13E4C5 n4:271B5452-363D-11E5-9242-09173F13E4C5 n4:271B5453-363D-11E5-9242-09173F13E4C5
n3:patent: n5:5716957 n5:5468755
n3:routeOfElimination: Parent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney.
n3:synonym: Bromoergocryptine 2-Bromo-alpha-ergocryptine 2-bromo-α-ergokryptine Bromocryptine 2-bromo-α-ergokryptin (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione 2-bromo-α-ergocryptine 2-Bromo-alpha-ergokryptine Bromocriptinum Bromocriptina (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman Bromoergocriptine 2-Bromo-alpha-ergokryptin
n3:toxicity: Symptoms of overdosage include nausea, vomiting, and severe hypotension. The most common adverse effects include nausea, headache, vertigo, constipation, light-headedness, abdominal cramps, nasal congestion, diarrhea, and hypotension.
n19:hasAHFSCode: n20:28-36-20-04
n3:foodInteraction: Avoid alcohol. Take with food to reduce irritation.
n3:proteinBinding: 90-96% bound to serum albumin
n3:synthesisReference: Luigi Moro, Achille Fiori, Alberto Natali, "Processes for the preparation of pharmaceutical compositions containing bromocriptine having high stability and related products." U.S. Patent US5066495, issued May, 1988.
n24:hasConcept: n25:M0002948
foaf:page: n27:bromocriptine.html n30:bromocriptine.htm
n3:IUPAC-Name: n10:271B546D-363D-11E5-9242-09173F13E4C5
n3:InChI: n10:271B5473-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n10:271B5472-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n10:271B546F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n10:271B5470-363D-11E5-9242-09173F13E4C5
n3:SMILES: n10:271B5471-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n10:271B546B-363D-11E5-9242-09173F13E4C5
n3:logP: n10:271B5484-363D-11E5-9242-09173F13E4C5 n10:271B5469-363D-11E5-9242-09173F13E4C5 n10:271B546C-363D-11E5-9242-09173F13E4C5
n3:logS: n10:271B546A-363D-11E5-9242-09173F13E4C5
n19:hasATCCode: n29:N04BC01 n29:G02CB01
n3:H-Bond-Acceptor-Count: n10:271B5479-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n10:271B547A-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n10:271B5474-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n10:271B5475-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n10:271B5477-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n10:271B5476-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n10:271B5478-363D-11E5-9242-09173F13E4C5
n3:absorption: Approximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 25614-03-3
n3:category
n3:containedIn: n21:271B545F-363D-11E5-9242-09173F13E4C5 n21:271B5460-363D-11E5-9242-09173F13E4C5 n21:271B545D-363D-11E5-9242-09173F13E4C5 n21:271B545E-363D-11E5-9242-09173F13E4C5 n21:271B545B-363D-11E5-9242-09173F13E4C5 n21:271B545C-363D-11E5-9242-09173F13E4C5 n21:271B5463-363D-11E5-9242-09173F13E4C5 n21:271B5461-363D-11E5-9242-09173F13E4C5 n21:271B5462-363D-11E5-9242-09173F13E4C5 n21:271B5464-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n10:271B547F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n10:271B5481-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n10:271B5482-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n10:271B5483-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n10:271B547E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n10:271B547D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n10:271B5480-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n10:271B546E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n10:271B547B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n10:271B547C-363D-11E5-9242-09173F13E4C5